Histological and molecular determinants in fertility-sparing treatment of endometrial cancer
Abstract
Purpose: The aim of this study was to evaluate the clinical outcomes, molecular signatures, and prognostic implications of histological features, including squamous metaplasia (SM), in endometrial cancer (EC)/ atypical hyperplasia (AH) patients under the age of 40 years with early-stage EC or AH and who received fertility-sparing treatment. Materials and Methods: This retrospective study included 16 patients who met the following criteria: EC or AH, aged ≤40 years, with no myometrial invasion or ≤50% depth of invasion, and a strong desire for fertility. The treatment consisted of oral progestins (megestrol acetate [MA]) combined with LNG-IUS for 3–12 months. Investigations included immunohistochemical analyses to assess the expression levels of p53 and mismatch repair proteins (MSH2, MSH6, MLH1, and PMS2). The cases were divided into three molecular groups (MMR-deficient [MMRd], p53 mutant [p53abn], and p53 wild-type [p53wt]). Results: All tumors were p53 wild-type (p53wt). Complete remission (CR) occurred in 38% (6/16) of cases, and stable disease was observed in 62% (10/16). SM was observed in 37.5% (6/16) of patients, and only one SM-positive patient achieved CR (p=0,182). Four patients (3 spontaneous, 1 assisted reproductive technologies) conceived 3 full-term pregnancies. CR was not associated with age, BMI, comorbidities, or the type of treatment. Conclusion: By highlighting the potential association between SM and lower CR rates, we provide a basis for future investigations into the clinical significance of this histological feature. SM may indicate resistance to hormonal therapy.
Keywords
Endometrial cancer , Fertility-sparing treatment , Squamous metaplasia , p53wt
Kaynakça
- Mutlu L, Manavella DD, Gullo G, McNamara B, Santin AD, Patrizio P. Endometrial cancer in reproductive age: Fertility-sparing approach and reproductive outcomes. Cancers. 2022;14:5187.
- Rodolakis A, Scambia G, Planchamp F, Acien M, Di Spiezio Sardo A, Farrugia M et al. ESGO/ESHRE/ESGE guidelines for the fertility-sparing treatment of patients with endometrial carcinoma. Hum Reprod Open. 2023;2023-57.
- Xu Y, Zhao M, Zhang L, Wang T, Wang B, Xue Y et al. Outcomes of fertility preservation treatments in patients with endometrial cancer with different molecular classifications based on an NGS panel. Front Oncol. 2023;13:1282356.
- Chung YS, Woo HY, Lee JY, Park E, Nam EJ, Kim S et al. Mismatch repair status influences response to fertility-sparing treatment of endometrial cancer. Am J Obstet Gynecol. 2021 224:370.e1–370.e13.
- Raffone A, Catena U, Travaglino A, Masciullo V, Spadola S, Della Corte L et al. Mismatch repair-deficiency specifically predicts recurrence of atypical endometrial hyperplasia and early endometrial carcinoma after conservative treatment: a multi-center study. Gynecol Oncol. 2021;161:795–801.
- Ran X, Hu T, Li Z. Molecular classification in patients with endometrial cancer after fertility-preserving treatment: application of proMisE classifier and combination of prognostic evidence. Front Oncol. 2022;12:810631.
- Zhao S, Zhang J, Yan Y, Tian L, Chen L, Zheng X et al. Oncological and reproductive outcomes of endometrial atypical hyperplasia and endometrial cancer patients undergoing conservative therapy with hysteroscopic resection: A systematic review and meta-analysis. Acta Obstet Gynecol Scand. 2024;103:1498-512.
- Gunderson CC, Fader AN, Carson KA, Bristow RE. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol. 2012;125:477‐82.
- Fan Z, Li H, Hu R, Liu Y, Liu X, Gu L. Fertility‐preserving treatment in young women with grade 1 presumed stage IA endometrial adenocarcinoma: a meta‐analysis. Int J Gynecol Cancer. 2018;28:385‐93.
- Agusti N, Kanbergs A, Nitecki R. Potential of molecular classification to guide fertility-sparing management among young patients with endometrial cancer. Gynecol Oncol. 2024;185:121-7.
